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The current work aimed at preparing a cyclo (Nα-dinicotinoyl)-bis-[(L-valinyl)-L-lysine] from previously established 
synthetic routs. The derivative was investigated for its potential anticancer activities as well as its possible mechanism of 
action. The prepared compound showed variable anticancer activities against all tested cell lines. Furthermore, it showed 
very promising activities in terms of obtained IC50 values compared to known used drugs. The mechanism of action studies 
showed that the prepared tripeptide may act on cancerous cells through its inhibitory action on tyrosine kinase pathway. 
Animal model experiments proved the potential of the synthesized tripeptide as an anticancer agent against PC3 cancer cells. 
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Introduction 
Carboxamide derivatives have biological and 
medicinal importance, such as: antimicrobial
1,2
, In 
vivo anti-inflammatory and In vitro antioxidant
3,4
, c-
Src kinase inhibitors
5
, antiviral
6
, anti-atherothrombosis
7
, 
antiemetic
8
, anxiolytic
9
, antimalarial and antileishmanial
10
 
activities. In previous publications
11–16
, we have shown 
that pyridine candidates are excellent derivatives for the 
synthesis of heterocyclic systems very interesting as 
anti-microbial, potential analgesic and anti-inflammatory, 
and anti-breast cancer agents. In continuation of our 
previous work
11–16
 in heterocyclic and peptide 
chemistry, herein we reported the anticancer activities 
against different cancer cell lines of cyclo (N
α
-
dinicotinoyl)-bis-[(L-valinyl)-L-lysine] derivative. 
 
Materials and Methods 
 
Chemistry 
The chemistry and characterization (physical and 
spectroscopic data) of 4 was reported previously by 
Amr et al.
17
 
Synthesis of methyl 4,14-diisopropyl-2,5,13,16-tetraoxo-
3,6,12,15-tetraaza-1(3,5)-pyridinacyclohexadecaphane-7-
carboxylate (3) by Mixed anhydride method18: 
A mixture of 2 (1 mmol) and ethyl chloroformate 
(2 mmol) in CH2Cl2 (25 mL) in the presence of TEA 
(2 mmol) was stirred for 20 min. at -20
o
C, then  
L-lysine methyl ester, (1 mmol) in CH2Cl2 (5 mL) 
was added at (-20
o
C) with stirring for 6 hrs and then 
overnight at room temperature. The mixture triturated 
with H2O, 1N HCl, 1N NaHCO3 and H2O to give 
derivative 3. The obtained product 4 was identified 
and comparison with authentic sample.
16
 
 
Synthesis of 4,14-diisopropyl-2,5,13,16-tetraoxo-3,6,12,15-
tetraaza-1(3,5)-pyridin-acyclohexadecaphane-7-carboxylic acid 
“cyclo (Nα-dinicotinoyl)-bis-[(L-valinyl)-L-lysine]” (4)  
To a cold mixture of 3 (1 mmol) in methanol  
(10 mL), methanolic sodium hydroxide was added  
at -5
o
C with stirringfor 3 hrs and for 12 h at  
room temperature. The mixture was acidified with 1 
N HCl to pH ≈ 3. The obtained solid was filtered off, 
washed with water, dried, and recrystallized from 
ethanol to afford the derivative4. The obtained 
product 4 was identified and comparison with 
authentic sample.
16
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Biological Activities  
 
Anticancer activities 
The prepared compound was evaluated for its 
anticancer activities against 17 different cancerous 
cell lines representing different cancer tissues and 
types. The assay depended on crystal violet staining
19
 
after formalin fixation for the cells exposed to 
different serial dilutions of the prepared compound. 
DMSO was used as solvent as well as negative 
control throughout the experiments, while different 
known pharmaceutical drugs were used as positive 
control to compare the expected activities of the 
compound with known used drugs. Briefly, cells  
were kept and propagated at standard cell culture 
conditions. Microtiter plates were seeded with 
exponentially growing cells at a concentration of 2  
10
4
/well, and were incubated for 24 h at 37C. 
Afterwards, wells received 50 μl of each serial 
dilution of the prepared compound and were further 
incubated for another 24 h. Then, the plates were 
inverted and shake to free cells from plates. 10% 
formalin was added as a fixative for 10 min, and then 
was thoroughly washed and aspirated. 0.09% crystal 
violet was used to stain the cells for 15 min, and then 
plates were washed with saline twice, examined and 
counted microscopically for differentiation between 
dead and living cells. IC50 values were determined 
from the linear regression curves of the obtained data. 
 
VEGFR-2 kinase activity  
The inhibitory effect of the synthesized compound 
(4) against VEGFR−2 tyrosine kinase enzyme was 
evaluated using ELISA technique as described in 
Zhang et al.
20
 The enzyme substrate/PBS was used to 
label well plates, which were then incubated for 12 h at 
37°C. Plates were washed and dried. Samples were 
added and then VEGFR-2 kinase were added. The 
reaction processed as normal and the antibody PY99 
was used, followed by peroxidase addition. OPD 
coloring solution was added and plates were incubated 
for 30 min. The reaction was terminated with 2 M 
H2SO4, and the absorbance was read at 490 nm. 
 
In vivo antiprostate cancer animal model  
Male Wistar rats were used to evaluate the 
antiprostate cancer activity in vivo according to 
Kinoyama et al.
21
 The used experiments depends on 
treating animals with androgen (testosterone 
propionate, 0.5 mg·kg
−1
, s.c.) for 5 days alone or in 
combination with our synthesized compound (10–30 
mg·kg
-1
, p.o.). The method followed the described 
specific protocol. The antiprostate cancer activities 
activity was determined as the fraction of inhibited 
testosterone propionate effect. 
 
Results and Discussion 
 
Chemistry 
In our previous work
17
, 4,14-diisopropyl-2,5,13,16-
tetraoxo-3,6,12,15-tetraaza-1(3,5)-pyridin-
acyclohexadecaphane-7-carboxylic acid ―cyclo (Nα-
dinicotinoyl)-bis-[(L-valinyl)- L-lysine]‖ (4) was 
synthesized by treating of compound 3 with 
methanolic sodium hydroxide, which was obtained 
from 3,5-pyridine dicarboxylic acid with L-valine 
methyl ester to give compound 2. Compound 2 was 
cyclized by reacting with L-lysine methyl ester 
(Mixed anhydride method) to give macrocyclic 
tripeptide 3 according to reported procedure
1
  
(Scheme 1). In the current study, we report the 
evaluation and activities of compound 4 as possible 
anticancer agent. 
 
Biological Screening 
 
Anticancer activities 
This section of the work was designed to evaluate 
the potential anticancer activities of compound 4 
against different cancerous cell lines. Results obtained 
and presented (Fig 1) clearly show that Compound  
4 has potential and promising anticancer activities 
against most of the tested cell lines. It can be seen that 
the recorded IC50 values varied according to cell type 
used. This is in great accordance with our previously 
reported work on anticancer activities of natural 
extracts and synthesized compounds.
16,22–24
 This  
can be mainly explained due to the variation in  
cell membrane structures between various cancerous 
cell types. 
Furthermore, in terms of IC50 values, it can be seen 
that the synthesized cyclo (N
α
-dinicotinoyl)-bis-[(L-
valinyl)-L-lysine has higher anticancer activities 
against HeLa (cervical), HT1080 (fibrosarcoma), 
K561 (leukemia), RKOP27 (colon), HepG2 (liver) 
and PC3 (prostate) cell lines. The activities  
increased by about 13.2-, 5.2-, 1.94-, 1.51-, 1.1-, 1.04-
folds from their corresponding positive control  
drugs. The obtained IC50 values for these cell lines 
recorded 1.56, 2.56, 3.43, 2.87, 3.17 and 3.44 nM, 
respectively, while their positive controls showed 
much higher IC50  
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Scheme 1 — Chemical structure for synthesized compounds20 
 
 
 
Fig. 1 — Cytotoxic activities of synthesized compound 4 against various tested cell lines 
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values of 11.8, 13.24, 6.66, 4.33, 3.44 and 8.22 nM 
for Paclitaxel, Imantinib, Doxorubicin, Capecitabine, 
Gemcitabine and Bicalutamide, respectively. On the 
other hand, the synthesized compound ineffective 
against KB (cervical), SKOV3 (ovarian), SF268 
(brain), NCIH460 (lung), HL60 (leukemia), U937 
(leukemia), G361 (melanoma), SKMEL28 (melanoma), 
NB1 (neuroblastoma) and MCF7 (breast) cell lines, 
when compared to their corresponding IC50 values 
obtained by the positive control drugs. For GOTO 
neuroblastoma cells, the synthesized compounds 
showed an IC50 value similar to that recorded for the 
positive control (4.67 and 4.73 nM for Cpd. 4 and 
Doxorubicin, respectively. 
 
Evaluation of possible mechanism of action 
The anti-VEGFR-2 activity assay of the tested 
compound was performed to gain an insight about its 
possible mechanism of action in comparison to the 
known Sorafenib control drug. Results showed that 
our newly synthesized cyclo (Nα-dinicotinoyl)-bis-[(L-
valinyl)-L-lysine inhibited the VEGFR-2 enzyme at an 
IC50 of 1.76 nM, which was about 18% higher than 
the IC50 obtained for the control Sorafenib (2.0 nM). 
These results suggest that the prepared compound 
exhibited its anticancer activity probably through the 
inhibition of the VEGFR-2 enzymatic action.  
 
Antiprostate cancer animal model 
The in vivo antiprostate cancer model was tested in 
male Wistar rats to evaluate the potential of the 
synthesized cyclo (N
α
-dinicotinoyl)-bis-[(L-valinyl)-
L-lysine derivative to exhibit antitumorigenic effects 
in animal models. Results showed that the tested 
derivative had an increased in vivo antitumorigenic 
activity, which was about 3.28-folds higher than the 
effect obtained for the positive control. The obtained 
ED50 values were 3.54±0.023 and 11.60±0.09 for 
compound 4 and Flutamide, respectively.  
 
Conclusions 
The current work was designed to investigate the 
possibility of synthesizing a new cyclo (N
α
-
dinicotinoyl)-bis-[(L-valinyl)-L-lysine peptide and to 
evaluate its in vitro as well as in vivo anticancer 
activities. Results showed that the obtained compound 
has a great anticancer potential against 6 out of  
17 tested cancerous cell lines, with variable degrees of 
cytotoxic effects depending on the cell line itself. 
Furthermore, the mechanism of action by which the 
synthesized compound is expected to exert its action 
is supposed to be through the inhibition of VEGFR-2 
enzymatic pathway. Additionally, animal model 
experiments proved the effectiveness of the newly 
synthesized peptide.  
 
Abbreviations 
IC50 Half maximal inhibitory concentration  
ED50 Median effective dose 
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